Polymer-Linked IL-7 Conjugates for Lower Immunogenicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cytokines like IL-7 stimulate an immune response against themselves, leading to antibody formation and reduced receptor expression, necessitating the development of less immunogenic and more sustained IL-7 therapies.
Innovation Solution
Conjugates of IL-7 moieties covalently attached to water-soluble polymers via releasable or non-releasable linkages, maintaining immune stimulation while reducing immunogenicity and sustaining receptor signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If IL-7 is administered therapeutically to stimulate the immune system, then immune system recovery is promoted, but immunogenicity increases causing antibody response against the therapeutic protein
Solution Approach 1:
The patent uses a polymer carrier as an intermediary substance to deliver the IL-7 cytokine. The polymer-IL-7 conjugate allows the therapeutic protein to be delivered while the polymer shield reduces direct immune recognition of the foreign protein structure, thereby maintaining immune stimulatory effects while reducing immunogenicity
Solution Approach 2:
The patent creates a composite material by covalently attaching IL-7 to a polymer backbone. This composite structure combines the biological activity of IL-7 with the reduced immunogenicity properties of the polymer, achieving both therapeutic efficacy and reduced antibody formation
2Reliability
If high levels of IL-7 are administered to achieve therapeutic effect, then immune cell proliferation is enhanced, but IL-7 receptor expression is profoundly reduced leading to sustained signaling loss
Solution Approach 1:
The patent employs a dynamic dosing strategy where the polymer-IL-7 conjugate provides controlled, sustained release of IL-7. This dynamic delivery system maintains IL-7 levels within a therapeutic window that stimulates immune cell proliferation without causing profound receptor downregulation, thereby sustaining long-term signaling capability
Solution Approach 2:
The patent utilizes periodic administration of the polymer-IL-7 conjugate to maintain therapeutic effects. The conjugate's sustained release properties allow for less frequent dosing compared to native IL-7, providing periodic stimulation that prevents receptor exhaustion while maintaining immune cell proliferation
Data Source
AI summary
Conjugates of an IL-7 moiety and one or more nonpeptidic, water-soluble polymers are provided. Typically, the non-peptidic, water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, and methods of administering compositions to an individual.